Matching articles for "page 40"
Issue 1312 · May 18, 2009 Free
In Brief: Plan B for 17-Year Olds

The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B 1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel…

Med Lett Drugs Ther. 2009 May 18; 51(1312):40
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B 1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B , taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception. 2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B . Fetal malformations have not been associated with pregnancies that occurred despite use of levonorgestrel-only emergency contraception. 3 1. Emergency contraception OTC. Med Lett Drugs Ther 2004; 46:10. 2. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352:428. 3. L Zhang et al. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod 2009 Mar 31 (epub). Download: U.S. English
Issue 1260 · May 7, 2007 Free
In Brief: Tegaserod (Zelnorm) Withdrawn

Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of…

Med Lett Drugs Ther. 2007 May 7; 49(1260):40
Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women, 1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect. 2 The FDA now has requested that the manufacturer stop marketing the drug based on an unpublished postmarketing analysis of earlier clinical trials that showed a higher rate of serious cardiovascular events (including angina, myocardial infarction and stroke) in patients who took tegaserod compared to placebo. Among more than 11,600 patients treated with tegaserod for 1-3 months, 13 (0.11%) had a confirmed ischemic event compared to only 1 patient (0.01%) among more than 7000 treated with placebo. The mechanism by which tegaserod would cause cardiovascular ischemia is unknown; serotonin 5-HT 1 receptor agonists used to treat migraine, such as sumatriptan (Imitrex) , can constrict coronary arteries, and tegaserod has some affinity for 5-HT 1 receptors. 3 Tegaserod may still be available, possibly through a special access program, for patients who do not have other treatment options. 1. Tegaserod maleate (Zelnorm) for IBS with constipation. Med Lett Drugs Ther 2002; 44:79. 2. Drugs for irritable bowel syndrome. Treat Guidel Med Lett 2006; 4:11. 3. AJ Busti et al. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24:526. Download U.S. English